ASCO 2023 (cont.)
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
Young Kwang Chae, Northwestern University, Chicago, IL, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/220010
I mpact of pregnancy in women with desmoid fibromatosis: An international retrospective observational study. Marco Fiore, MD, FACS, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/218386 Famitinib for familial adenomatous polyposis-associated aggressive desmoid tumors: A single- center exploratory study. Sai Ge, Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China, et. al. Abstract: https://meetings.asco.org/abstracts-presentations/218434
International Patient Advocacy Group Meeting
Desmoid patient advocacy groups from around the world were hosted by the Italian group, Desmoid Foundation ONLUS Associazione Italiana Tumore Desmoide, at the end of June. DTRF Executive Director, Jeanne Whiting, participated in discussions with and presented to this inspiring workgroup.
Together we're stronger! DTRF holds an annual Desmoid Tumor Global Roundtable with international patient advocacy groups as we all work together to advocate for patients around the world.
DTRF Leadership Team Attends CTOS 2023
Lynne Hernandez, DTRF Executive Director, and Jeanne Whiting, DTRF Executive Director Emeritus and attended CTOS 2023 in Dublin, Ireland, November 1-4.
The team was honored to connect and collaborate with other patient advocacy groups, researchers and industry professionals. The conference was filled with energy and the promise of accelerating science toward more treatment options for desmoid tumor and all sarcoma patients. Last year's 2022 designation of desmoid tumors as “Sarcoma of the Year” reflected a year of groundbreaking research in our rare disease. Researchers from varied backgrounds presented multiple scientific posters about desmoid tumors.
12
Made with FlippingBook Online newsletter maker